Screener
Rapport Therapeutics, Inc. RAPP Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Rapport Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Rapport Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:30 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333862
| Line item | For the six monthsended June 30, 2026 | For the six monthsended June 30, 2025 |
|---|---|---|
| Accounts payable | (1,374) | 1,216 |
| Accrued expenses and other current liabilities | 11,086 | 784 |
| Operating lease liabilities | (1,379) | (111) |
| Net cash used in operating activities | (54,516) | (45,307) |
| Cash flows from investing activities | ||
| Purchases of short-term investments | (70,044) | (56,093) |
| Sale of short-term investments | 10,075 | - |
| Maturities of short-term investments | 123,481 | 100,033 |
Item 1. Financial Statements.
FAQ
- What is Rapport Therapeutics, Inc.'s operating cash flow?
- Rapport Therapeutics, Inc. (RAPP) reported operating cash flow of -$41.46M in Q2 2026.
- How has Rapport Therapeutics, Inc.'s operating cash flow changed year-over-year?
- Rapport Therapeutics, Inc.'s operating cash flow decreased by 65.4% year-over-year, from -$25.07M to -$41.46M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Rapport Therapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude